Diabetic nephropathy.
Castellino
P
P
University of Napoli, Italy.
Tuttle
K R
KR
DeFronzo
R A
RA
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000449:Aldehyde Reductase / Q000037:antagonists & inhibitors; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000818:Animals; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D001786:Blood Glucose / Q000378:metabolism; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D003924:Diabetes Mellitus, Type 2 / Q000503:physiopathology; D003928:Diabetic Nephropathies / Q000188:drug therapy / Q000628:therapy*; D018753:Diet, Protein-Restricted; D004232:Diuretics / Q000627:therapeutic use; D015444:Exercise; D006031:Glycosylation / Q000187:drug effects; D006146:Guanidines / Q000627:therapeutic use; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000628:therapy*; D010972:Platelet Activating Factor; D051381:Rats; D013004:Somatostatin / Q000031:analogs & derivatives / Q000627:therapeutic use; D015431:Weight Loss
D000319:Adrenergic beta-Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D001786:Blood Glucose; D002121:Calcium Channel Blockers; D004232:Diuretics; D006146:Guanidines; D010972:Platelet Activating Factor; D013004:Somatostatin; D000449:Aldehyde Reductase; C004479:pimagedine